Anebulo Pharmaceuticals Secures $994,300 NIH Grant for Pediatric Cannabis Toxicity Drug Trial
Anebulo Pharmaceuticals Inc. has secured a $994,300 grant from the NIH to support its Phase 1 study of selonabant, aimed at treating acute cannabis-induced toxicity in children. The study, approved by the FDA, focuses on the drug's safety and pharmacokinetics. The company is collaborating with NIDA and the FDA to develop selonabant for pediatric use.
Anebulo Pharmaceuticals Inc. announced it has been awarded the second-year tranche of a collaborative grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH), totaling $994,300, to support its ongoing Phase 1 single ascending dose study of an intravenous formulation of its lead drug candidate, selonabant. The study, cleared by the FDA, is investigating the safety, tolerability, and pharmacokinetics of selonabant for the treatment of acute cannabis-induced toxicity in children. The company highlighted ongoing collaborative support from NIDA and noted that the FDA has encouraged close collaboration to facilitate the development of selonabant for pediatric use. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anebulo Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251113842608) on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
